DE1271116B - Process for the preparation of 4-hydroxypyrimidines - Google Patents

Process for the preparation of 4-hydroxypyrimidines

Info

Publication number
DE1271116B
DE1271116B DEP1271A DE1271116A DE1271116B DE 1271116 B DE1271116 B DE 1271116B DE P1271 A DEP1271 A DE P1271A DE 1271116 A DE1271116 A DE 1271116A DE 1271116 B DE1271116 B DE 1271116B
Authority
DE
Germany
Prior art keywords
calculated
found
carbon atoms
general formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEP1271A
Other languages
German (de)
Inventor
Dr Hans-Joachim Kabbe
Dr Karl Eiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DEP1271A priority Critical patent/DE1271116B/en
Publication of DE1271116B publication Critical patent/DE1271116B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

BUNDESREPUBLIK DEUTSCHLANDFEDERAL REPUBLIC OF GERMANY

DEUTSCHESGERMAN

PATENTAMTPATENT OFFICE

AUSLEGESCHRIFTEDITORIAL

Int. Cl.:Int. Cl .:

Deutsche KL:German KL:

Nummer:
Aktenzeichen:
Anmeldetag:
Auslegetag:
Number:
File number:
Registration date:
Display day:

C07dC07d

A61kA61k

12 ρ-7/01
30 h-2/36
12 ρ -7/01
30 h-2/36

1271116
P 12 71 116.9-44
4. Mai 1965
27.Juni 1968
1271116
P 12 71 116.9-44
May 4, 1965
June 27, 1968

Gegenstand der Erfindung ist ein Verfahren zur Herstellung von 4-Hydroxypyrimidinen; das Verfahren besteht darin, daß man Essigsäureester der allgemeinen FormelThe invention relates to a process for the preparation of 4-hydroxypyrimidines; the procedure consists in that one acetic acid ester of the general formula

R1 — CH2 — COOR2 IR 1 - CH 2 - COOR 2 I.

in der R1 einen gegebenenfalls durch Halogenatome oder Alkylgruppen mit 1 bis 6 Kohlenstoffatomen oder durch Alkoxy- oder Alkylmercaptogruppen mit 1 bis 4 Kohlenstoffatomen oder durch Hydroxy- oder Aminogruppen oder durch Alkylamino- oder Dialkylaminogruppen mit 1 bis 4 Kohlenstoffatomen, wobei zwei dieser Alkylreste zusammen mit dem Stickstoffatom einen heterocyclischen Ring bilden können, substituierten Phenyl- oder Naphthylrest darstellt, oder einen gegebenenfalls durch Alkylgruppen mit 1 bis 6 Kohlenstoffatomen substituierten, 1 bis 3 gleiche oder verschiedene Heteroatome N, S oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet, und in der R2 für einen Alkylrest mit 1 bis 6 Kohlenstoffatomen steht, mit Nitrilen der allgemeinen Formel Verf ahren zur Herstellung von
4-Hydroxypyrimidinen
in which R 1 is optionally by halogen atoms or alkyl groups with 1 to 6 carbon atoms or by alkoxy or alkyl mercapto groups with 1 to 4 carbon atoms or by hydroxy or amino groups or by alkylamino or dialkylamino groups with 1 to 4 carbon atoms, two of these alkyl radicals together with the nitrogen atom can form a heterocyclic ring, substituted phenyl or naphthyl radical, or a 5- or 6-membered ring optionally substituted by alkyl groups with 1 to 6 carbon atoms, containing 1 to 3 identical or different heteroatoms N, S or O, on which also a Benzene ring can be fused, and in which R 2 is an alkyl radical having 1 to 6 carbon atoms, with nitriles of the general formula Process for the preparation of
4-hydroxypyrimidines

R3 R 3

CNCN

in der R3 einen 1 bis 3 gleiche oder verschiedene Heteroatome N, S oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet, in Gegenwart einer der Menge des Essigsäureesters mindestens äquimolaren Menge eines Alkalialkoholats eines niederen Alkohols, eines Alkaliamids oder hochsiedenden tertiären Amins, gegebenenfalls in Gegenwart eines inerten organischen Lösungsmittels bei Temperaturen zwischen 60 und 1600C zu 4-Hydroxypyrimidinderivaten der allgemeinen Formelin which R 3 denotes a 5- or 6-membered ring containing 1 to 3 identical or different heteroatoms N, S or O, to which a benzene ring can also be fused, in the presence of an amount of an alkali metal alcoholate of a lower alcohol which is at least equimolar to the amount of the acetic acid ester , an alkali amide or high-boiling tertiary amine, optionally in the presence of an inert organic solvent at temperatures between 60 and 160 ° C. to give 4-hydroxypyrimidine derivatives of the general formula

OHOH

in der R1 und R3 die oben angegebenen Bedeutungen haben, umsetzt.in which R 1 and R 3 have the meanings given above.

Für die Durchführung des erfindungsgemäßen Verfahrens geeignete Essigsäureester der allgemeinen Formel I sind z. B. Phenylessigsäuremethylester, -äthylester, -isopropylester und -butylester, «- und /y-Naphthylessigsäureäthylester, o-, m- und p-Methylphenylessigsäureäthylester, o-, m- und p-Methoxyphenylessigsäureäthylester, o-, m- und p-Methylmercaptophenylessigsäurcäthylester, o-, m- und p-Hydroxy-For carrying out the process according to the invention, suitable acetic acid esters of the general Formula I are e.g. B. Phenylacetic acid methyl ester, ethyl ester, isopropyl ester and butyl ester, «- and / y-naphthylacetic acid ethyl ester, o-, m- and p-methylphenylacetic acid ethyl ester, o-, m- and p-methoxyphenylacetic acid ethyl ester, o-, m- and p-methyl mercaptophenylacetic acid ethyl ester, o-, m- and p-hydroxy

Anmelder:Applicant:

Farbenfabriken Bayer Aktiengesellschaft,Paint factories Bayer Aktiengesellschaft,

5090 Leverkusen5090 Leverkusen

Als Erfinder benannt:Named as inventor:

Dr. Hans-Joachim Kabbe, 5090 Leverkusen;Dr. Hans-Joachim Kabbe, 5090 Leverkusen;

Dr. Karl Eiter, 5000 Köln-StammheimDr. Karl Eiter, 5000 Cologne-Stammheim

phenylessigsäureäthylester, o- und p-Chlorphenylessigsäureäthylester, 3 - Chlor - 4 - methoxyphenylessigsäureäthylester, 3,4 - Dichlorphenylessigsäureäthylester, 3,5 - Dichlor - 4- methoxyphenylessigsäureäthylester, 2-Methoxy-4-methyl-5-chlorphenylessigsäureäthylester, p-Aminophenylessigsäureäthylester, p-Methylaminophenylessigsäureäthylester, ρ - Dimethylaminophenylessigsäureäthylester, p-Pyrrolidinophenylessigsäureäthylester, α - Furylessigsäureäthylester, α-, β- und y-Pyridylessigsäureäthylester, 5-Thiazolylessigsäureäthylester, 5 - Oxazolylessigsäureäthylester, 1 - vic - Triazolylessigsäureäthylester und 2 - Benzimidazolylessigsäureäthylester. phenylacetic acid ethyl ester, o- and p-chlorophenylacetic acid ethyl ester, 3 - chloro - 4 - methoxyphenylacetic acid ethyl ester, 3,4 - dichlorophenylacetic acid ethyl ester, 3,5 - dichloro - 4-methoxyphenylacetic acid ethyl ester, 2-methoxy-4-methyl-5-chlorophenylacetic acid ethyl ester, p-ethyl aminophenylacetate, p- -Methylaminophenylacetic acid ethyl ester, ρ - dimethylaminophenylacetic acid ethyl ester, p-pyrrolidinophenylacetic acid ethyl ester, α - furyl acetic acid ethyl ester, α-, β- and γ-pyridyl acetic acid ethyl ester, 5-thiazolylacetic acid ethyl ester, 5-oxazolylacetic acid ethyl ester, 2 acetylacetate, 5-oxazolylacetyl acetic acid ethyl ester, benzoliacetyl acetate, benzyl acetate, 5-oxazolylacetyl acetate, benzyl acetate, ethyl acetate.

Geeignete Nitrile der allgemeinen Formel II sind beispielsweise 2-Cyanopyrrol, 2-Cyanofuran, 2-Cyanothiophen, α-, β- und y-Cyanopyridin, 4- und 5-Cyanothiazol, 4- und 5-Cyanooxazol, 4-Cyanopyrimidin und 3-Cyanochinolin.Suitable nitriles of the general formula II are, for example, 2-cyanopyrrole, 2-cyanofuran, 2-cyanothiophene, α-, β- and γ-cyanopyridine, 4- and 5-cyanothiazole, 4- and 5-cyanooxazole, 4-cyanopyrimidine and 3- Cyanoquinoline.

Das Molverhältnis zwischen Essigsäureestern und Nitrilen beträgt im allgemeinen 1:1,5 bis 1:3, zweckmäßig 1:2.The molar ratio between acetic acid esters and nitriles is generally 1: 1.5 to 1: 3, expedient 1: 2.

Als Alkalialkoholate eignen sich z. B. Kalium- und Natriummethylat, -äthylat, -tert.butylat, als Alkaliamide ζ. B. Kalium- und Natriumamid, als hochsiedende tertiäre Amine ζ. B. Dimethylanilin, Collidin und Chinolin.Suitable alkali metal alcoholates are, for. B. potassium and sodium methylate, ethylate, tert-butylate, as alkali amides ζ. B. potassium and sodium amides, as high-boiling tertiary amines ζ. B. dimethylaniline, collidine and quinoline.

Die Umsetzung, deren Dauer 15 Minuten bis 10 Stunden beträgt, wird vorzugsweise zwischen 100 und 130' C durchgeführt. Falls Lösungsmittel verwendet werden, müssen sie gegenüber den zur Anwendung gelangenden Essigsäureestern und Nitrilen sowie gegenüber den oben angegebenen basischen Verbindungen inert sein und, falls die Umsetzung unterImplementation, the duration of which is 15 minutes up 10 hours is preferably carried out between 100 and 130 ° C. If solvent is used they must be compared to the acetic acid esters and nitriles used as well be inert towards the basic compounds given above and, if the reaction is below

809 567/566809 567/566

normalem Druck vorgenommen wird, mindestens einen der Umsetzungstemperatur entsprechenden Siedepunkt besitzen. Als Beispiele seien genannt Kohlenwasserstoffe, wie Benzol, Toluol und Xylol, Äther, wie Dibutyläther und Glykoldiäthyläther, Alkohole, wie Butanol und Pentanol, und chlorierte Kohlenwasserstoffe, wie Tetrachlorkohlenstoff, Di-1 chloräthan und Chlorbenzol.normal pressure is carried out, at least one corresponding to the reaction temperature Have boiling point. Examples are hydrocarbons such as benzene, toluene and xylene, Ethers such as dibutyl ether and glycol diethyl ether, alcohols such as butanol and pentanol, and chlorinated ones Hydrocarbons such as carbon tetrachloride, di-1 chloroethane and chlorobenzene.

Die nach dem erfindungsgemäßen Verfahren überraschenderweise erhaltenen neuen 4-Hydroxypyrimidine der allgemeinen Formel III besitzen eine bemerkenswerte Wirkung gegenüber Bakterien, wie Streptokokken, Staphylokokken, Colibakterien, Proteusbakterien und Tuberkelbakterien, sowie gegen Pilze, wie Trichophyton mentagrophytes und Candida albicans.Surprisingly, by the process according to the invention obtained new 4-hydroxypyrimidines of the general formula III have a remarkable Effect on bacteria such as streptococci, staphylococci, coli bacteria, proteus bacteria and tubercle bacteria, as well as against fungi such as Trichophyton mentagrophytes and Candida albicans.

Die in den folgenden Beispielen angegebenen Teile sind Gewichtsteile.The parts given in the following examples are parts by weight.

Beispiel 1example 1

33 Teile Phenylessigsäureäthylester (0,2 Mol) und 42 Teile a-Cyanopyridin (0,4 Mol) wurden bei Raumtemperatur mit 12 Teilen Natriummethylat (0,22 Mol) verrührt und dann erwärmt. Bei 60° C trat eine stark exotherme Reaktion ein, und die Temperatur stieg dann bis auf 115° C. Die Reaktionsmischung wurde anschließend noch 20 Minuten auf 1100C gehalten, dann abgekühlt und in 250 Teilen Wasser gelöst. Aus der erhaltenen Lösung wurde durch Zugabe von 100 Teilen gesättigter wäßriger Ammoniumchloridlösung das gebildete 2,6-Di-a-pyridyl-4-hydroxy-5-phenylpyrimidin ausgefällt. Die Ausbeute betrug 40 Teile (= 62%), Schmelzpunkt 227 bis 228,5° C (nach dem Umkristallisieren aus Eisessig—Wasser).33 parts of ethyl phenylacetate (0.2 mol) and 42 parts of α-cyanopyridine (0.4 mol) were stirred with 12 parts of sodium methylate (0.22 mol) at room temperature and then heated. At 60 ° C, a strongly exothermic reaction occurred, and the temperature then rose to 115 ° C. The reaction mixture was then another 20 minutes to 110 0 C held, then cooled and dissolved in 250 parts of water. The 2,6-di-a-pyridyl-4-hydroxy-5-phenylpyrimidine formed was precipitated from the solution obtained by adding 100 parts of saturated aqueous ammonium chloride solution. The yield was 40 parts (= 62%), melting point 227 to 228.5 ° C. (after recrystallization from glacial acetic acid-water).

Analyse: C20H14N4O (326,35).Analysis: C 20 H 14 N 4 O (326.35).

Berechnet ... C 73,61, H 4,33, N 17,17%;
gefunden .... C 73,73, H 4,66, N 16,95%.
Calculated ... C 73.61, H 4.33, N 17.17%;
found .... C 73.73, H 4.66, N 16.95%.

Beispiel 2Example 2

Eine Mischung aus 33 Teilen Phenylessigsäureäthylester 0,2 Mol), 42 Teilen γ - Cyanopyridin (0,4 Mol) und 80 Teilen Butanol wurde mit 12 Teilen Natriummethylat (0,22 Mol) versetzt und IV2 Stunden bei HO0C gerührt. Dann wurde die Reaktionsmischung in 250 Teilen Wasser gelöst. Durch Zugabe von 100 Teilen gesättigter wäßriger Ammoniumchloridlösung wurde das gebildete 2,6-Di-y-pyridyl-4-hydroxy-5-phenylpyrimidin ausgefällt. Die Ausbeute betrug 61 Teile (= 800/o), Schmelzpunkt 300 bis 3050C (nach dem Umkristallisieren aus Eisessig— Wasser).A mixture of 33 parts of phenylacetic acid ethyl ester (0.2 mol), 42 parts of γ- cyanopyridine (0.4 mol) and 80 parts of butanol was mixed with 12 parts of sodium methylate (0.22 mol) and stirred at HO 0 C for IV2 hours. Then the reaction mixture was dissolved in 250 parts of water. The 2,6-di-y-pyridyl-4-hydroxy-5-phenylpyrimidine formed was precipitated by adding 100 parts of saturated aqueous ammonium chloride solution. The yield was 61 parts (= 80 0 / o), m.p. 300-305 0 C (after recrystallization from glacial acetic acid water).

Analyse: C20H14N4O · CH3COOH (386,39).
Berechnet ... N 14,50%;
gefunden .... N 14,67%.
Analysis: C 20 H 14 N 4 O • CH 3 COOH (386.39).
Calculated ... N 14.50%;
found .... N 14.67%.

Verwendete man an Stelle von Natriummethylat die äquivalente Menge an Kalium-tert.-butylat, so erhielt man das 2,6-Di-y-pyridyl-4-hydroxy-5-phenylpyrimidin in 78%iger Ausbeute.If the equivalent amount of potassium tert-butoxide was used instead of sodium methylate, see above the 2,6-di-y-pyridyl-4-hydroxy-5-phenylpyrimidine was obtained in 78% yield.

In analoger Weise wurden die aus der folgenden Tabelle ersichtlichen Essigsäureäthylester der allgemeinen Formel I in Gegenwart von Natriummethylat mit Nitrilen der allgemeinen Formel II zu den entsprechenden 4-Hydroxypyrimidinen der allgemeinen Formel III umgesetzt.In an analogous manner, the ethyl acetate shown in the following table were the general Formula I in the presence of sodium methylate with nitriles of the general formula II converted to the corresponding 4-hydroxypyrimidines of the general formula III.

Die Umsetzung des in der Tabelle unter n) angeführten 3,4-DichlorphenyIessigsäureäthylesters mit 2-Cyanofuran wurde ohne Mitverwendung eines Lösungsmittels vorgenommen; die Umsetzung des unter a) angeführten Phenylessigsäureäthylesters mit ^-Cyanopyridin erfolgte unter Mitverwendung von Pentanol als Lösungsmittel, und die übrigen Umsetzungen wurden unter Mitverwendung von Butanol als Lösungsmittel durchgeführt.The implementation of the 3,4-dichlorophenyl acetic acid ethyl ester listed in the table under n) with 2-cyanofuran was carried out without the use of a solvent; the implementation of the under a) listed phenylacetic acid ethyl ester with ^ -Cyanopyridin took place with the use of Pentanol as the solvent, and the remaining reactions were carried out with the use of butanol carried out as a solvent.

R1 R 1 R3 R 3 Reaktionsdauer/
Reaktions
temperatur
Response time /
Reaction
temperature
Aus
beute
the end
prey
Schmelzpunkt
in 0C
Melting point
in 0 C
Summenformel von IIIMolecular formula of III
a)a) 3 Stunden
1100C
3 hours
110 0 C
3939 308 bis 313308 to 313 C20H14N4O
berechnet: N 17,17;
gefunden: N 16,98.
C 20 H 14 N 4 O
calculated: N 17.17;
found: N 16.98.
OH
I
OH
I.
b)b) OHOH νV-νV-
\ /\ /
2 Stunden
1100C
2 hours
110 0 C
3030th 320
(Zersetzung)
320
(Decomposition)
C20H14N4O3
berechnet: N 15,63;
gefunden: N 15,28.
C 20 H 14 N 4 O 3
calculated: N 15.63;
found: N 15.28.
ClCl c)c) //—N // —N 4 Stunden
110° C
4 hours
110 ° C
5151 >300> 300 C20H13ClN4O
berechnet: N 15,55, Cl 9,83;
gefunden: N 15,55, Cl 9,90.
C 20 H 13 ClN 4 O
Calculated: N 15.55, Cl 9.83;
found: N 15.55, Cl 9.90.
ClCl d)d) <^<^ 3 Stunden
110° C
3 hours
110 ° C
3535 232 bis 238232 to 238 C20H13ClN4O
berechnet: Cl 9,83;
gefunden: Cl 9,85.
C 20 H 13 ClN 4 O
calculated: Cl 9.83;
found: Cl 9.85.

Fortsetzungcontinuation

R1 R 1

R3 R 3

Reaktionsdauer/ Reaktionstemperatur Reaction time / reaction temperature

Ausbeute yield

Schmelzpunkt
in °C
Melting point
in ° C

Summenformel von HIMolecular formula of HI

ClCl

CH3OCH 3 O

3 Stunden 1100C3 hours 110 ° C

3 Stunden 1100C3 hours 110 ° C

4 Stunden 1100C4 hours 110 ° C

5 Stunden 1050C5 hours 105 ° C

I1I2 Stunden HO0C I 1 I 2 hours HO 0 C

3 Stunden 1150C3 hours 115 ° C

3 Stunden 105° C3 hours 105 ° C

2 Stunden 1100C2 hours 110 ° C

1 Stunde 1100C1 hour 110 ° C

4 Stunden 1050C4 hours 105 ° C

6 Stunden 1080C6 hours 108 0 C

IV2 Stunden 105°CIV2 hours 105 ° C

bis 295to 295

bis 222to 222

bis 285to 285

>330> 330

bis 252to 252

212 bis 213212 to 213

bis 286to 286

bis 303to 303

bis 266to 266

320320

bis 252to 252

bis 221to 221

C20H13ClN4OC 20 H 13 ClN 4 O

berechnet: N 15,53, Cl 9,83; gefunden: N 15,48, Cl 9,85.Calculated: N 15.53, Cl 9.83; found: N 15.48, Cl 9.85.

C20H13ClN4OC 20 H 13 ClN 4 O

berechnet: Cl 9,83; gefunden: Cl 9,95.calculated: Cl 9.83; found: Cl 9.95.

C20H13ClN4OC 20 H 13 ClN 4 O

berechnet: N 15,53; gefunden: N 15,33.calculated: N 15.53; found: N 15.33.

C20H13ClN4OC 20 H 13 ClN 4 O

berechnet: N 15,53, Cl 9,83; gefunden: N 15,15, Cl 9,80.Calculated: N 15.53, Cl 9.83; found: N 15.15, Cl 9.80.

C21H15ClN4O2 C 21 H 15 ClN 4 O 2

berechnet: N 14,34, Cl 9,07; gefunden: N 14,36, Cl 8,75.Calculated: N 14.34, Cl 9.07; found: N 14.36, Cl 8.75.

C20H12Cl2N4OC 20 H 12 Cl 2 N 4 O

berechnet: N 14,18, Cl 17,94; gefunden: N 14,19, Cl 17,55.Calculated: N 14.18, Cl 17.94; found: N 14.19, Cl 17.55.

C20N12Cl2N4OC 20 N 12 Cl 2 N 4 O

berechnet: Cl 17,94; gefunden: Cl 18,15.calculated: Cl 17.94; found: Cl 18.15.

C20H12Cl2N4O · 1,5 CH3COOHC 20 H 12 Cl 2 N 4 O.1.5 CH 3 COOH

berechnet: N 11,54; gefunden: N 11,40.calculated: N 11.54; found: N 11.40.

C18H10Cl2N2O3 C 18 H 10 Cl 2 N 2 O 3

berechnet: N 7,51, O 12,88; gefunden: N 7,53, 0 13,13.Calculated: N 7.51, O 12.88; found: N 7.53, 0 13.13.

C20H12ClN4OC 20 H 12 ClN 4 O

berechnet:calculated:

C 60,77, H 3,06, N 14,17; gefunden:C 60.77, H 3.06, N 14.17; found:

C 60,44, H 3,25, N 14,37.C 60.44, H 3.25, N 14.37.

C24H16N4OC 24 H 16 N 4 O

berechnet: N 14,88; gefunden: N 14,70.calculated: N 14.88; found: N 14.70.

C19H13N5OC 19 H 13 N 5 O

berechnet:calculated:

C 69,71, H 4,01, N 21,40; gefunden:C 69.71, H 4.01, N 21.40; found:

C 69,37, H 4,27, N 20,97.C 69.37, H 4.27, N 20.97.

Fortsetzungcontinuation

R1 R 1

R3 R 3

Reaktionsdauer/ Reaktionstemperatur Reaction time / reaction temperature

Ausbeute Schmelzpunkt
in 0C
Yield melting point
in 0 C

Summenformel von IIIMolecular formula of III

Q-Q-

4 Stunden 115°C4 hours 115 ° C

2 Stunden 1080C2 hours 108 0 C

IV2 Stunden 1150CIV2 hours 115 0 C

Claims (1)

Patentanspruch:Claim: Verfahren zur Herstellung von 4-Hydroxypyrimidinen, dadurch gekennzeichnet, daß man Essigsäureester der allgemeinen FormelProcess for the preparation of 4-hydroxypyrimidines, characterized in that that one acetic acid ester of the general formula R^CH2-COOR2 R ^ CH 2 -COOR 2 in der R1 einen gegebenenfalls durch Halogenatome oder Alkylgruppen mit 1 bis 6 Kohlenstoffatomen oder durch Alkoxy- oder Alkylmercaptogruppen mit 1 bis 4 Kohlenstoffatomen oder durch Hydroxy- oder Aminogruppen oder durch Alkylamino- oder Dialkylaminogruppen mit 1 bis 4 Kohlenstoffatomen, wobei zwei dieser Alkylreste zusammen mit dem Stickstoff einen heterocyclischen Ring bilden können, substituierten Phenyl- oder Naphthylrest darstellt, oder einen gegebenenfalls durch Alkylgruppen mit 1 bis 6 Kohlenstoffatomen substituierten, 1 bis 3 gleiche oder verschiedene Heteroatome N, S oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet, und in der R2 für einen Alkylrest mit 1 bis 6 Kohlenstoff-in which R 1 is optionally by halogen atoms or alkyl groups with 1 to 6 carbon atoms or by alkoxy or alkyl mercapto groups with 1 to 4 carbon atoms or by hydroxy or amino groups or by alkylamino or dialkylamino groups with 1 to 4 carbon atoms, two of these alkyl radicals together with the nitrogen can form a heterocyclic ring, substituted phenyl or naphthyl radical, or a 5- or 6-membered ring optionally substituted by alkyl groups with 1 to 6 carbon atoms, containing 1 to 3 identical or different heteroatoms N, S or O, on which also a Benzene ring can be fused, means, and in which R 2 is an alkyl radical with 1 to 6 carbon 266 bis 267266 to 267 230
(Zersetzung)
230
(Decomposition)
196 bis 199196 to 199 C22H15N5OC 22 H 15 N 5 O berechnet: N 19,17; gefunden: N 19,10.calculated: N 19.17; found: N 19.10. C16H11N7O · 2V2 H2OC 16 H 11 N 7 O.2V 2 H 2 O berechnet:calculated: C 53,02, H 4,45, N 27,06; gefunden:C 53.02, H 4.45, N 27.06; found: C 53,22, H 4,26, N 27,22.C 53.22, H 4.26, N 27.22. C18H12N4O2 C 18 H 12 N 4 O 2 berechnet: C 68,34, H 3,83; gefunden: C 68,49, H 4,20.Calculated: C 68.34, H 3.83; found: C 68.49, H 4.20. atomen steht, mit Nitrilen der allgemeinen Formel R3—CNatoms, with nitriles of the general formula R 3 —CN in der R3 einen 1 bis 3 gleiche oder verschiedene Heteroatome N, S oder O enthaltenden 5- oder 6gliedrigen Ring, an den auch ein Benzolring anelliert sein kann, bedeutet, in Gegenwart einer der Menge des Essigsäureesters mindestens äquimolaren Menge eines Alkalialkoholats eines niederen Alkohols, eines Alkaliamids oder hochsiedenden tertiären Amins, gegebenenfalls in Gegenwart eines inerten organischen Lösungsmittels bei Temperaturen zwischen 60 und 1600C zu 4-Hydroxypyrimidinderivaten der allgemeinen Formelin which R 3 denotes a 5- or 6-membered ring containing 1 to 3 identical or different heteroatoms N, S or O, to which a benzene ring can also be fused, in the presence of an amount of an alkali metal alcoholate of a lower alcohol which is at least equimolar to the amount of the acetic acid ester , an alkali amide or high-boiling tertiary amine, optionally in the presence of an inert organic solvent at temperatures between 60 and 160 ° C. to give 4-hydroxypyrimidine derivatives of the general formula OHOH R1 R 1 R3 R 3 OjOOjO R3 R 3 in der R1 und R3 die oben angegebenen Bedeutungen haben, umsetzt.in which R 1 and R 3 have the meanings given above. 809 567/566 6.68 © Bundesdruckerei Berlin809 567/566 6.68 © Bundesdruckerei Berlin
DEP1271A 1965-05-04 1965-05-04 Process for the preparation of 4-hydroxypyrimidines Pending DE1271116B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEP1271A DE1271116B (en) 1965-05-04 1965-05-04 Process for the preparation of 4-hydroxypyrimidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP1271A DE1271116B (en) 1965-05-04 1965-05-04 Process for the preparation of 4-hydroxypyrimidines
DEF0045958 1965-05-04

Publications (1)

Publication Number Publication Date
DE1271116B true DE1271116B (en) 1968-06-27

Family

ID=25751381

Family Applications (1)

Application Number Title Priority Date Filing Date
DEP1271A Pending DE1271116B (en) 1965-05-04 1965-05-04 Process for the preparation of 4-hydroxypyrimidines

Country Status (1)

Country Link
DE (1) DE1271116B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557860A1 (en) * 1992-02-28 1993-09-01 Bayer Ag Substituted pyridiylpyrimidines and their use as parasiticide
WO1998024780A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
EP1314732A2 (en) * 1996-12-05 2003-05-28 Amgen Inc. Substituted pyrimidine compounds and their use
WO2005099711A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US11993580B1 (en) 2023-12-01 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557860A1 (en) * 1992-02-28 1993-09-01 Bayer Ag Substituted pyridiylpyrimidines and their use as parasiticide
US5385905A (en) * 1992-02-28 1995-01-31 Bayer Aktiengesellschaft Substituted pyridylpyrimidines
WO1998024780A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
WO1998024780A3 (en) * 1996-12-05 1998-07-30 Amgen Inc Substituted pyrimidinone and pyridinone compounds and their use
WO1998024782A3 (en) * 1996-12-05 1998-08-27 Amgen Inc Substituted pyrimidine compounds and their use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6420385B1 (en) 1996-12-05 2002-07-16 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP1314732A2 (en) * 1996-12-05 2003-05-28 Amgen Inc. Substituted pyrimidine compounds and their use
EP1314731A2 (en) * 1996-12-05 2003-05-28 Amgen Inc. Substituted pyrimidine compounds and their use
US6610698B2 (en) 1996-12-05 2003-08-26 Amgen, Inc. Substituted pyrimidine compounds and methods of use
US6649604B2 (en) 1996-12-05 2003-11-18 Amgen Inc. Substituted pyridone compounds and methods of use
EP1314732A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
EP1314731A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
WO2005099711A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7560464B2 (en) 2004-04-13 2009-07-14 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US11993580B1 (en) 2023-12-01 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Similar Documents

Publication Publication Date Title
DE1670529C3 (en) Substituted s-triazines
DE1470439B1 (en) Quinoline derivatives and processes for their preparation
DE2237632C3 (en) H4-Hydro3qr-6-methyl-2-pvrimidinyD-3-methyl-pyrazolin-5-one, a process for its preparation and its use for the preparation of 1- (4-methoxy-6methyl-2-pyrimidinyl) -3-methyl -5-methoxypyrazole
DE1271116B (en) Process for the preparation of 4-hydroxypyrimidines
DE1169939B (en) Process for the preparation of dihalo-aminobenzylamines or their acid addition salts with physiologically acceptable acids
DE2141616C3 (en) Oxazole- and Oxazine square bracket on 3.2-c square bracket for quinazolinone, process for their preparation and medicinal products containing these compounds
DE2841644C2 (en)
DE1795344A1 (en) 3-amino-isothiazoles
CH638203A5 (en) Process for preparing substituted aminoquinazoline derivatives
DE2804263C3 (en) Process for the preparation of indoline derivatives
DE1233405B (en) Process for the preparation of 7- (oxoalkyl) -1, 3-dimethylxanthines
DE2162917C3 (en)
DE2407904A1 (en) D-2-SUBST.-6-ALKYL-8-SUBST.-ERGOLINE AND THE PROCESS FOR THEIR PRODUCTION
DE1770922A1 (en) New triazine derivatives and processes for their preparation
DE1000387C2 (en) Process for the preparation of new 1, 10-diazaanthracenes substituted in the 9-position
DE1695757C3 (en) Pyridine methanol carbamates and processes for their preparation
DE1135478B (en) Process for the preparation of 3, 5-dioxo-1, 2, 4-triazolidines
DE1695757B2 (en) PYRIDINE METHANOL CARBAMATES AND PROCESS FOR THE PREPARATION
DE1083803B (en) Process for the preparation of derivatives of anthranil-N-carboxylic acid
AT394193B (en) Process for the preparation of novel 5-fluoronicotinic acids or derivatives and salts thereof
AT266838B (en) Process for the preparation of benzodiazepine derivatives
DE1720012C3 (en) Process for the preparation of 2,4-diamino-5- (3,4,5-trimethoxybenzyl) pyrimidine
DE1670730A1 (en) Process for the preparation of quinoxaline di-N-oxides
DE3229215A1 (en) 1- (HALOGENALKYL) -1,2,3,4-TETRAHYDRO-SS-CARBOLINE, THEIR PRODUCTION AND USE
DE1518633A1 (en) Process for the preparation of pharmaceutically active derivatives of 2-aminoindane